Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption.

2005年6月13日 · Alefacept is a recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1.

2021年8月22日 · Alefacept 是人类白细胞功能相关抗原（LAF）-3 与 CD2 结合的细胞外部分与人免疫球蛋白 Ig G 重链的绞链区和稳定区（CH2 和 CH3）部分融合而成的二聚体蛋白。 其与活化的 T 细胞表面的 CD2 分子结合，从而阻断抗原呈递细胞（APC）对 T 细胞的共刺激。 此外，其选择性地靶向记忆效应 T 细胞，从而二者都起到抑制 T细胞活化和消耗记忆性 T 细胞的作用。 随着越来越多的生物制剂出现，Alefacept 在银屑病治疗中的地位越来越低。 2013 年一项关于银屑 …

2019年8月23日 · 阿法西普（Alefacept） 是 FDA 批准用于治疗银屑病的首个生物制剂，随着越来越多的生物制剂出现，Alefacept 在银屑病治疗中的地位越来越低。2011 年 Alefacept 退出市场。

2021年9月15日 · Alefacept is a recombinant fusion protein of lymphocyte function associated antigen-3 (LFA-3) and immunoglobulin G dimer that acts to block the activation of T cells, and is an immunosuppressive agent that was previously …

2012年1月3日 · Alefacept (Amevive) is a fusion protein that combines the lymphocyte function-associated antigen 3 (LFA-3) with IgG1. Alefacept inhibits the activation of T cells by interfering with the CD2 receptor on T cells, blocking the costimulatory molecule LFA-3/CD2, blocking T-cell proliferation. It also induces apoptosis of effector memory T cells.

Alefacept is one of the first biologics in the treatment of psoriasis. It selectively reduces CD45RO(+) memory T cells and inhibits T-cell activation. Clinical data support its safety and efficacy in a substantial subset of patients with psoriasis.

Amevive (alefacept) is an immunosuppressive dimeric fusion protein that reduces lymphocyte counts (T-cells) thus treating the cause of psoriasis. It is indicated in patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy

2002年5月1日 · Alefacept modulates the function of and selectively induces apoptosis of CD2(+) human memory-effector T cells in vivo. We have sought to gain further understanding of the mechanisms of action that influence the biological activity of alefacept and may contribute to its efficacy and patient responsiveness.

Alefacept injection is used to treat chronic plaque psoriasis, which is a skin disease with red and white scales that don't go away. This medicine is given to patients who have used other medicines that did not work well. Alefacept is an immunosuppressant. It works on the immune system to treat the symptoms of plaque psoriasis.